Related Articles
Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study
Clinical and molecular assessment of regorafenib monotherapy
Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure
TUFM‑knockdown inhibits the migration and proliferation of gastrointestinal stromal tumor cells